NEUROCRINE BIOSCIENCES INC 8-K

What Happened

• Neurocrine Biosciences, Inc. announced its financial results for the fourth quarter and fiscal year ended December 31, 2025, in an 8-K dated February 11, 2026. The company attached the related press release as Exhibit 99.1 to the Current Report on Form 8-K.
• The filing is made under Item 2.02 (Results of Operations and Financial Condition) and the exhibit is furnished (not deemed “filed”) in accordance with General Instruction B.2 of Form 8-K. The report is signed by Matthew C. Abernethy, Chief Financial Officer.

Key Details

• Event date: February 11, 2026 (press release and 8-K filing).
• Reporting period: Fourth quarter and fiscal year ended December 31, 2025.
• Exhibit included: Press release dated February 11, 2026 attached as Exhibit 99.1.
• Legal note: Information is furnished under Form 8-K and is not subject to Section 18 liability or automatic incorporation by reference unless expressly stated.

Why It Matters

• The 8-K signals the company has released its latest earnings and financial performance; investors should review the attached press release for revenue, profit/loss, EPS, cash flow, and any updated guidance that could affect the stock.
• Because the press release is furnished (not filed), stakeholders should read the exhibit itself for the detailed metrics and rely on subsequent filings (e.g., 10-K, 10-Q) for audited or more comprehensive financial disclosures.